Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is an important regulator of T cell or B cell antigen receptor signaling.
MALT1 is activated by genetic changes in various types of lymphomas.
CTX-177 is a selective small molecule inhibitor of MALT1, with manufacturing and commercial rights granted to Ono Pharmaceutical Co., Ltd. in 2020.
Phase I clinical studies are expected to be conducted at Ono Pharmaceutical Co., Ltd.